Veracyte's TrueMRD Monitoring Test Receives CMS Coverage
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2026
0mins
Veracyte announced that its TrueMRD Monitoring Test has received coverage from the Centers for Medicare & Medicaid Services', CMS, Molecular Diagnostics Services Program for patients with muscle-invasive bladder cancer, MIBC. The TrueMRD Test is covered for recurrence monitoring following definitive treatment with curative intent in patients with MIBC. It will be available for clinicians to order on June 1, 2026, marking the commercial launch of Veracyte's first molecular residual disease, MRD, offering and the only commercially available truly whole-genome MRD test to come to market, expanding the company's reach into cancer recurrence monitoring.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VCYT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VCYT
Wall Street analysts forecast VCYT stock price to fall
5 Analyst Rating
3 Buy
1 Hold
1 Sell
Moderate Buy
Current: 47.990
Low
43.00
Averages
46.25
High
50.00
Current: 47.990
Low
43.00
Averages
46.25
High
50.00
About VCYT
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Prosigna Test Guides Chemotherapy Decisions in Breast Cancer
- New Standard for Chemotherapy Decisions: The OPTIMA trial reveals that 68% of high-risk node-positive breast cancer patients can safely forgo chemotherapy, achieving a 5-year cancer-free survival rate of 93.7%, statistically comparable to the 94.9% in the chemotherapy group, marking a significant shift in treatment decision-making.
- Broad Applicability: The trial confirmed non-inferiority across various high-risk subgroups, including premenopausal women and patients with extensive nodal involvement, indicating that tumor biology can guide chemotherapy decisions, enhancing treatment precision in clinical practice.
- Prospective Evidence: Involving 4,429 patients, the OPTIMA trial provides Level 1A evidence that the Prosigna test can accurately predict chemotherapy benefits and support safe de-escalation for high-risk patients, thereby reducing unnecessary side effects.
- Significant Clinical Impact: The study results will be presented at the ASCO Annual Meeting, expected to transform how clinicians approach breast cancer treatment decisions, enabling patients to opt for therapies with fewer side effects.
See More
Veracyte to Host Conference Call for 2026 ASCO Meeting
- Conference Details: Veracyte will host a conference call on June 1, 2026, at 8:30 a.m. ET to discuss data from two significant phase III clinical trials, showcasing the company's ongoing innovation in cancer diagnostics.
- Clinical Trial Results: The call will focus on results from the OPTIMA and ENZAMET trials, highlighting Veracyte's leadership in cancer detection technology, which could have profound implications for future treatment options.
- Expert Participation: Professor Iain Macpherson, a leading investigator from the University of Glasgow, will join the discussion, enhancing the professionalism and authority of the meeting.
- Live Webcast and Replay: The conference will be webcast live from the company's website, with a replay available afterward, ensuring that investors and healthcare professionals can access critical information at their convenience, thereby improving communication efficiency with stakeholders.
See More
Veracyte Unveils ENZAMET Study Data for Prostate Cancer
- Clinical Trial Results: Veracyte will present data from the OPTIMA and ENZAMET phase III clinical trials at the 2026 ASCO Annual Meeting, expected to provide practice-changing evidence for treatment decisions in early-stage breast cancer and metastatic prostate cancer, potentially impacting thousands of patients' treatment plans.
- OPTIMA Study Highlights: Enrolling over 4,400 patients, this study aims to identify which patients can safely avoid chemotherapy, thereby reducing long-term toxicities; results from the Prosigna test will provide Level 1A evidence for adjuvant chemotherapy decisions in high-risk breast cancer, potentially transforming clinical treatment approaches.
- ENZAMET Study Analysis: The ENZAMET trial will showcase how the Decipher Prostate test predicts treatment benefits for metastatic hormone-sensitive prostate cancer patients receiving triplet therapy, enabling clinicians to more accurately match treatment intensity to patient risk, thus avoiding unnecessary treatments.
- Strategic Implications: The findings from Veracyte not only offer personalized guidance for cancer treatment but also demonstrate the company's leadership in transforming cancer care globally, further solidifying its competitive position in the cancer diagnostics market.
See More
Veracyte Secures Medicare Coverage for TrueMRD Test in Bladder Cancer
- First Medicare Coverage: Veracyte's TrueMRD Monitoring Test has received coverage from Medicare, marking a significant milestone in the muscle-invasive bladder cancer (MIBC) space, which is expected to enhance patient recurrence monitoring capabilities and drive market acceptance.
- Commercial Launch: The test will be commercially available starting June 1, 2026, becoming the only whole-genome MRD test on the market, which is anticipated to significantly strengthen Veracyte's competitive position in cancer recurrence monitoring.
- Clinical Evidence Support: In a pivotal study involving over 900 samples, the TrueMRD test detected disease recurrence a median of 131 days earlier than imaging, showcasing its potential in early recurrence detection and possibly transforming monitoring practices for MIBC patients.
- Future Expansion Opportunities: Veracyte plans to expand the TrueMRD platform across multiple cancer types in the coming years, leveraging its whole-genome analysis capabilities to enhance tracking of tumor clonality and molecular evolution, thereby providing more precise treatment options for patients.
See More
Veracyte Reports Strong Q1 Earnings, Shares Up 23%
- Significant Earnings Growth: Veracyte's Q1 sales increased by 21%, with earnings per share quadrupling and net income margin rising from 6% to 21%, all surpassing Wall Street expectations, indicating robust profitability and market demand.
- Strong Product Sales: The company's leading product, Decipher for prostate cancer detection, saw a 24% sales increase, while Afirma for thyroid cancer rose by 12%, reinforcing Veracyte's market leadership in cancer diagnostics.
- New Product Launch Plans: Veracyte is set to launch Prosigna for breast cancer detection by mid-year and TrueMRD targeting muscle-invasive bladder cancer in Q2, showcasing its ongoing innovation and market expansion potential.
- Solid Financial Position: With nearly $400 million in net cash against a market cap of $3.3 billion, Veracyte's strong cash flow positions it well for future growth through potential acquisitions or new product lines, making it an intriguing growth stock for investors.
See More
Veracyte Reports 21% Revenue Growth in Q1 with Quadrupled EPS
- Significant Revenue Growth: Veracyte's Q1 revenue increased by 21% year-over-year, surpassing Wall Street expectations, indicating strong market demand in cancer detection, particularly for prostate and thyroid cancer tests which are growing at double-digit rates.
- Enhanced Profitability: The company's earnings per share quadrupled compared to last year, with net income margin improving from 6% to 21%, reflecting successful cost control and providing financial support for future investments and expansions.
- Market Share Stability: Decipher and Afirma hold 33% and 38% market shares in their respective prostate and thyroid cancer detection markets, indicating that Veracyte's products have become the standard of care for physicians, further solidifying its market leadership.
- Strong Cash Flow: With nearly $400 million in net cash against a market cap of $3.3 billion, Veracyte demonstrates financial health, positioning itself for potential acquisitions or the launch of next-generation tests to sustain growth.
See More
Prosigna Test Guides Chemotherapy Decisions in Breast Cancer
- New Standard for Chemotherapy Decisions: The OPTIMA trial reveals that 68% of high-risk node-positive breast cancer patients can safely forgo chemotherapy, achieving a 5-year cancer-free survival rate of 93.7%, statistically comparable to the 94.9% in the chemotherapy group, marking a significant shift in treatment decision-making.
- Broad Applicability: The trial confirmed non-inferiority across various high-risk subgroups, including premenopausal women and patients with extensive nodal involvement, indicating that tumor biology can guide chemotherapy decisions, enhancing treatment precision in clinical practice.
- Prospective Evidence: Involving 4,429 patients, the OPTIMA trial provides Level 1A evidence that the Prosigna test can accurately predict chemotherapy benefits and support safe de-escalation for high-risk patients, thereby reducing unnecessary side effects.
- Significant Clinical Impact: The study results will be presented at the ASCO Annual Meeting, expected to transform how clinicians approach breast cancer treatment decisions, enabling patients to opt for therapies with fewer side effects.
See More
Veracyte to Host Conference Call for 2026 ASCO Meeting
- Conference Details: Veracyte will host a conference call on June 1, 2026, at 8:30 a.m. ET to discuss data from two significant phase III clinical trials, showcasing the company's ongoing innovation in cancer diagnostics.
- Clinical Trial Results: The call will focus on results from the OPTIMA and ENZAMET trials, highlighting Veracyte's leadership in cancer detection technology, which could have profound implications for future treatment options.
- Expert Participation: Professor Iain Macpherson, a leading investigator from the University of Glasgow, will join the discussion, enhancing the professionalism and authority of the meeting.
- Live Webcast and Replay: The conference will be webcast live from the company's website, with a replay available afterward, ensuring that investors and healthcare professionals can access critical information at their convenience, thereby improving communication efficiency with stakeholders.
See More
Veracyte Unveils ENZAMET Study Data for Prostate Cancer
- Clinical Trial Results: Veracyte will present data from the OPTIMA and ENZAMET phase III clinical trials at the 2026 ASCO Annual Meeting, expected to provide practice-changing evidence for treatment decisions in early-stage breast cancer and metastatic prostate cancer, potentially impacting thousands of patients' treatment plans.
- OPTIMA Study Highlights: Enrolling over 4,400 patients, this study aims to identify which patients can safely avoid chemotherapy, thereby reducing long-term toxicities; results from the Prosigna test will provide Level 1A evidence for adjuvant chemotherapy decisions in high-risk breast cancer, potentially transforming clinical treatment approaches.
- ENZAMET Study Analysis: The ENZAMET trial will showcase how the Decipher Prostate test predicts treatment benefits for metastatic hormone-sensitive prostate cancer patients receiving triplet therapy, enabling clinicians to more accurately match treatment intensity to patient risk, thus avoiding unnecessary treatments.
- Strategic Implications: The findings from Veracyte not only offer personalized guidance for cancer treatment but also demonstrate the company's leadership in transforming cancer care globally, further solidifying its competitive position in the cancer diagnostics market.
See More
Veracyte Secures Medicare Coverage for TrueMRD Test in Bladder Cancer
- First Medicare Coverage: Veracyte's TrueMRD Monitoring Test has received coverage from Medicare, marking a significant milestone in the muscle-invasive bladder cancer (MIBC) space, which is expected to enhance patient recurrence monitoring capabilities and drive market acceptance.
- Commercial Launch: The test will be commercially available starting June 1, 2026, becoming the only whole-genome MRD test on the market, which is anticipated to significantly strengthen Veracyte's competitive position in cancer recurrence monitoring.
- Clinical Evidence Support: In a pivotal study involving over 900 samples, the TrueMRD test detected disease recurrence a median of 131 days earlier than imaging, showcasing its potential in early recurrence detection and possibly transforming monitoring practices for MIBC patients.
- Future Expansion Opportunities: Veracyte plans to expand the TrueMRD platform across multiple cancer types in the coming years, leveraging its whole-genome analysis capabilities to enhance tracking of tumor clonality and molecular evolution, thereby providing more precise treatment options for patients.
See More
Veracyte Reports Strong Q1 Earnings, Shares Up 23%
- Significant Earnings Growth: Veracyte's Q1 sales increased by 21%, with earnings per share quadrupling and net income margin rising from 6% to 21%, all surpassing Wall Street expectations, indicating robust profitability and market demand.
- Strong Product Sales: The company's leading product, Decipher for prostate cancer detection, saw a 24% sales increase, while Afirma for thyroid cancer rose by 12%, reinforcing Veracyte's market leadership in cancer diagnostics.
- New Product Launch Plans: Veracyte is set to launch Prosigna for breast cancer detection by mid-year and TrueMRD targeting muscle-invasive bladder cancer in Q2, showcasing its ongoing innovation and market expansion potential.
- Solid Financial Position: With nearly $400 million in net cash against a market cap of $3.3 billion, Veracyte's strong cash flow positions it well for future growth through potential acquisitions or new product lines, making it an intriguing growth stock for investors.
See More
Veracyte Reports 21% Revenue Growth in Q1 with Quadrupled EPS
- Significant Revenue Growth: Veracyte's Q1 revenue increased by 21% year-over-year, surpassing Wall Street expectations, indicating strong market demand in cancer detection, particularly for prostate and thyroid cancer tests which are growing at double-digit rates.
- Enhanced Profitability: The company's earnings per share quadrupled compared to last year, with net income margin improving from 6% to 21%, reflecting successful cost control and providing financial support for future investments and expansions.
- Market Share Stability: Decipher and Afirma hold 33% and 38% market shares in their respective prostate and thyroid cancer detection markets, indicating that Veracyte's products have become the standard of care for physicians, further solidifying its market leadership.
- Strong Cash Flow: With nearly $400 million in net cash against a market cap of $3.3 billion, Veracyte demonstrates financial health, positioning itself for potential acquisitions or the launch of next-generation tests to sustain growth.
See More
